ModerateDirect oral anticoagulants (factor Xa inhibitors)×Selective serotonin reuptake inhibitor (SSRI)
Updated · Methodology
Mechanism
Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Paroxetine is a selective serotonin reuptake inhibitor (SSRI). A pharmacodynamic interaction may occur between paroxetine and oral anticoagulants: together they may increase anticoagulant activity and the risk of bleeding (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Drugs that interfere with serotonin reuptake, paroxetine included, increase the risk of bleeding, and anticoagulants may add to this risk (US paroxetine prescribing information, US Food and Drug Administration, FDA). The edoxaban SmPC warns that, as with other anticoagulants, SSRIs may raise the risk of bleeding through their reported effect on platelets (edoxaban SmPC, EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding into the skin (bruising and purpura) and gastrointestinal and gynaecological bleeding have been reported with selective serotonin reuptake inhibitors (SSRIs), paroxetine included. Older patients may have a higher risk of non-menstrual bleeding (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Such bleeding has ranged from bruising, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (US paroxetine prescribing information, US Food and Drug Administration, FDA).
Management
The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Use paroxetine with caution in patients taking oral anticoagulants and in patients with previous bleeding or conditions that predispose to bleeding (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient about the increased risk of bleeding (US paroxetine prescribing information, US Food and Drug Administration, FDA). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Paroxetina (nº registro 59466), sección 4.5 (2025)– AEMPS, CIMA, nº registro 59466 (Frosinor 20 mg, GlaxoSmithKline), revisión 12/2025, secciones 4.4, 4.5, 4.8 y 5.1
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2